CytomX Therapeutics Inc (NASDAQ:CTMX) has been assigned a consensus rating of “Buy” from the thirteen brokerages that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $21.32.
Several research firms have recently issued reports on CTMX. BidaskClub downgraded CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, April 16th. ValuEngine downgraded CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, February 27th. SunTrust Banks decreased their price target on CytomX Therapeutics to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 28th. Zacks Investment Research downgraded CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, March 5th. Finally, HC Wainwright reiterated a “buy” rating and set a $34.00 price target on shares of CytomX Therapeutics in a research note on Wednesday, April 3rd.
In related news, General Counsel Lloyd A. Rowland bought 9,000 shares of the company’s stock in a transaction dated Monday, March 4th. The stock was acquired at an average cost of $10.33 per share, with a total value of $92,970.00. Following the acquisition, the general counsel now owns 9,979 shares in the company, valued at approximately $103,083.07. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 6.30% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Legal & General Group Plc boosted its position in shares of CytomX Therapeutics by 15.3% in the 3rd quarter. Legal & General Group Plc now owns 7,036 shares of the biotechnology company’s stock worth $130,000 after purchasing an additional 934 shares during the last quarter. BNP Paribas Arbitrage SA boosted its position in shares of CytomX Therapeutics by 84,072.7% in the 1st quarter. BNP Paribas Arbitrage SA now owns 9,259 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 9,248 shares during the last quarter. Deltec Asset Management LLC bought a new position in shares of CytomX Therapeutics in the 1st quarter worth $129,000. Metropolitan Life Insurance Co. NY boosted its position in shares of CytomX Therapeutics by 376.5% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 13,479 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 10,650 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale boosted its position in shares of CytomX Therapeutics by 21.5% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 14,700 shares of the biotechnology company’s stock worth $334,000 after purchasing an additional 2,600 shares during the last quarter. 86.67% of the stock is owned by institutional investors.
Shares of CTMX stock traded up $0.12 on Friday, reaching $10.72. 8,590 shares of the company’s stock traded hands, compared to its average volume of 455,126. CytomX Therapeutics has a 12-month low of $8.94 and a 12-month high of $27.20. The company has a current ratio of 4.21, a quick ratio of 4.21 and a debt-to-equity ratio of 0.22. The company has a market capitalization of $492.08 million, a price-to-earnings ratio of -5.30 and a beta of 0.57.
CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Thursday, May 9th. The biotechnology company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.22. CytomX Therapeutics had a negative return on equity of 73.62% and a negative net margin of 111.27%. The company had revenue of $29.49 million for the quarter, compared to analyst estimates of $13.59 million. On average, sell-side analysts predict that CytomX Therapeutics will post -2.07 EPS for the current year.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
Further Reading: Institutional Investors
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.